People: Trius Therapeutics Inc (TSRX.W)

TSRX.W on CBOE When Trading NASDAQ Global Select Market

7.79USD
20 May 2013
Price Change (% chg)

$-0.20 (-2.50%)
Prev Close
$7.99
Open
$8.05
Day's High
$8.14
Day's Low
$7.79
Volume
1,100
Avg. Vol
3,049
52-wk High
$8.40
52-wk Low
$4.44

Search Stocks

Eastham, Karin 

Brief Biography

Ms. Karin Eastham, CPA, is Independent Director of Trius Therapeutics Inc., since November 2009. From May 2004 to September 2008, she served as executive vice president and chief operating officer, and as a member of the board of trustees of the Burnham Institute for Medical Research, a non-profit corporation engaged in basic biomedical research. From April 1999 to May 2004, Ms. Eastham served as senior vice president, finance, chief financial officer and secretary of Diversa Corporation, a publicly held renewable energy company which was subsequently renamed Verenium Corporation. She previously held similar positions with CombiChem, Inc., a computational chemistry company, and Cytel Corporation, a biopharmaceutical company. Ms. Eastham also held several positions, including vice president, finance, at Boehringer Mannheim Corporation from 1976 to 1988. Ms. Eastham also serves as a director for Amylin Pharmaceuticals, Inc., Geron Corporation and Illumina, Inc. Ms. Eastham received a B.S. and an M.B.A. from Indiana University and is a Certified Public Accountant and a Certified Director.

Basic Compensation

Total Annual Compensation, Long-Term Incentive Plans, All Other, Fiscal Year Total,
-- -- -- --

Options Compensation

  Quantity Market Value
Excercisable -- --
Unexercisable -- --
Excercised -- --
Name Fiscal Year Total

David Kabakoff

--

Jeffrey Stein

817,419

John Schmid

475,051

John Finn

434,554

Michael Morneau

--

Kenneth Bartizal

395,641
As Of 30 Dec 2011
Search Stocks